Clinical Trials Logo

Allergic Rhinitis (Disorder) clinical trials

View clinical trials related to Allergic Rhinitis (Disorder).

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01436851 Completed - Clinical trials for Allergic Rhinitis (Disorder)

Nasal Provocation Testing in Occupational Rhinitis

NPT
Start date: November 24, 2010
Phase: N/A
Study type: Interventional

In a previous study the investigators found that many bakery workers were sensitized to storage mites, and many had rhinitis symptoms. The role of storage mites as an occupational allergen with clinical relevance has been questioned, and the investigators wanted to investigate whether a nasal provocation with a storage mite extract would trigger symptoms and objective signs of rhinitis in bakery workers and a control group.

NCT ID: NCT01326247 Completed - Clinical trials for Allergic Rhinitis (Disorder)

Effectiveness Of Therapy With A Thermal Water Nasal Aerosol In Children With Seasonal Allergic Rhinitis

Start date: April 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study was to evaluate the effects of Ischia thermal waters nasal irrigation on allergic rhinitis and airway inflammation during the period of natural exposure to parietaria pollen in children with allergic rhinitis and intermittent asthma.

NCT ID: NCT01231464 Completed - Clinical trials for Rhinitis, Allergic, Perennial

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis

Start date: September 2009
Phase: Phase 3
Study type: Interventional

The objective of this study is to compare the efficacy and safety of Fluticasone Furoate Nasal Spray (FFNS), that is FFNS with placebo in Chinese adult and adolescent subjects with Allergic Rhinitis as AR. There are 3 phases, 2 to14 day run in, 2 week treatment, and 3 to 5 day follow up. After run in period, at least 360 subjects with AR ( ages of 12yrs and 65yrs, inclusive) will be randomised to receive FFNS 110ug once daily or placebo for 2 weeks. The primary endpoint is the change from baseline of reflective total nasal symptom score (rTNSS) during treatment period, and the secondary endpoints include mean change from baseline in nasal finding scores by rhinoscopy at completion of study treatment, and severity of overall inference in activities of daily living. Safety measures include AE (Adverse Event) reports, ECGs (Electrocardiograph), physical exams, vital signs, and nasal exam. In addition, reflective total ocular symptom score (rTOSS) will be measured as an explorative endpoint, only in the specific AR (Allergic Rhinitis) patients with severe ocular symptoms.

NCT ID: NCT01068808 Completed - Clinical trials for Allergic Rhinitis (Disorder)

The Development of Allergic Rhinitis in Children Previously Diagnosed as Nonallergic Rhinitis

Start date: January 2010
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate development of allergic rhinitis in children with nonallergic rhinitis.